Compare BFLY & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | CTMX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | N/A | 2015 |
| Metric | BFLY | CTMX |
|---|---|---|
| Price | $4.10 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.00 | ★ $12.10 |
| AVG Volume (30 Days) | ★ 5.7M | 2.9M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $24.01 | N/A |
| Revenue Next Year | $19.93 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.32 | $1.72 |
| 52 Week High | $5.72 | $8.21 |
| Indicator | BFLY | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 32.30 |
| Support Level | $3.71 | $3.39 |
| Resistance Level | $4.03 | $3.91 |
| Average True Range (ATR) | 0.36 | 0.20 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 7.65 | 1.45 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.